A

Ascension | St. Clair Nephrology Research

Research site

(Unclaimed)

Location

18001 East 10 Mile Road, Suite 3, Roseville, Michigan, United States of America

Site insights

Top conditions

Top treatments

VX-147

Lesinurad

BI 764198

RGLS8429

RGLS4326

Cyclosporine

CXA-10

Tacrolimus

Parent organization

This site is a part of Ascension

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling

Chronic Kidney Diseases

Type 2 Diabetes Mellitus

Biological: Renal Autologous Cell Therapy (REACT)

Procedure: Sham Comparator

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Primary Objectives* To assess the safety and tolerability of RGLS8429* To assess the impact of RGLS8429 on ADPKD biomarkersSecondary Objectives* To a...

Enrolling

ADPKD

Polycystic Kidney, Autosomal Dominant

Drug: Placebo

Drug: RGLS8429

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out...

Active, not recruiting

Kidney Disease, Chronic

Drug: BI 764198

Drug: Placebo

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147